The iPhone as a Physician Resource
Now that Apple has opened its iPhone to third-party software developers, healthcare productivity programs are leading the charge. Here?s a preview of one of the frontrunners.
Hillary, Obama or Mccain?
What will the next president really mean for US healthcare policy? PwC's Sandy Lutz reports.
A Slow Year for Pharma–with a Few Exceptions
The US pharma market grew just 3.8 percent last year, according to IMS Health. The big loser: lipid regulators. The winners: Biologic response modulators and monoclonal antibodies.
Edelman Trust Study Released
Pharma is still having a hard time earning the confidence of the key opinion elite, as only 56 percent claim they trust the industry.
Public Approves of Pharma Products, Dislikes Cost
A Kaiser Foundation study finds that although most Americans look favorably upon pharmaceuticals, they generally think drugs are too expensive and that most of the cost is blown on advertising.
PACME final brochure
PACME brochure
Michigan ePrescribing Program Shows Positive Results
A review of a pilot ePrescribing program reveals that if physicians are given the proper support, the technology can increase safer prescribing habits and boost compliance.
Open Season on FDA
Congress is firing plenty of ammunition at pharma companies-and the regulators
Study Rescue
Pharma companies must quit wasting money and get strategic when mapping out their clinical study strategies
Earning the Public Trust—and Keeping It
The industry needs credibility with consumers to make a spoonful of risk go down. So how does pharma speak to top concerns?
Nasonex: Most-Recalled TV Spot of 2007
IAG Research released its top-10 list of most-recalled new pharma ads of 2007. Many familiar faces top the list, including the Nasonex bee, Abe Lincoln, and Dr. Jarvik, but how many of those faces will still be there next year?
Pharma Still Taking Baby Steps on the Web
Avenue A|Razorfish's new digital-outlook report indicates that pharma is still floundering online. Though some pharma companies are taking steps to make their online presence known, others are still crawling.
Jarvik Ads Get KO'd
Under pressure from Congress and public scrutiny, Pfizer voluntarily pulled its controversial television campaign for Lipitor featuring Dr. Jarvik.
Possible Prescription-Tier Drop for Vytorin
A new study shows that while doctors aren't in a rush to stop prescribing Vytorin, they are considering it less often as a first-line treatment option.
Jarvik Ads Draw Fire
Pfizer's consumer ads for Lipitor are causing a stir on the blogs and in Congress. Did the company cross the line by using a famous (but unlicensed) doctor to market a drug, or is this a case of a mistaken identity?
Top Drug Sites for Consumers
More and more consumers are surfing the Web for information about prescription drugs, but many bypass brand.com sites, a new report says.
Healthcare Education Services extends oncology course portfolio
Healthcare Education Services has announced details of two additional oncology specific courses to add to its comprehensive range of medical education for the pharmaceutical industry.
Lilly Faces Billion-Dollar Settlement
Lilly is in the midst of settlement discussions with federal prosecutors over the pharma company?s off-label marketing of the antipsychotic medication Zyprexa. If settled, Lilly could be shelling out more than $1 billion in fines.
Grand Jury Probe Targets Merck Marketing Practices
Merck is under investigation for allegedly pushing physicians to prescribe Vioxx for unapproved use. Federal investigators are scrutinizing Merck?s marketing and sales practices in search of shady business tactics.
Rights to Japan: Q&A with Steve Engen, Japan Bridge
Global marketing strategies and the business opportunities in Japan
Funding Follies at FDA
Congress blocked DTC user fees, Reagan-Udall, field force reforms while slightly bumping FDA's budget
Wholesale Change: UK Responds to the Single-Supplier Practice
Will the sole-wholesaler approach mean higher costs for NHS?
Vermont Amends Data Mining Law
After watching similar legislation barring data mining for Rx info get shut down in Maine and New Hampshire, Vermont changes tactics and amends its law.
Vytorin Scripts Plummet
In the wake of the ENHANCE study, new prescriptions of the cholesterol-lowering drug Vytorin are dropping drastically, but calls to sales reps by physicians are on the rise.
Vytorin Study Causes Media Stir, but Are the Concerns Justified?
Unlike Vioxx, Vytorin works exactly as explained in its now-famous food-and-family ads. So why are people up in arms against the drug? Experts ponder what went wrong.
FDA Puts Kibosh on DTC User Fee Program
In a surprising but not completely unexpected move, FDA announced last week that its Prescription Drug User Fee Act was dead on arrival. Feds cite lack of funding as main reason.
Novartis Takes Top Spot in Managed Care Audit--Again
Managed care pharmacy executives list their favorite pharmaceutical companies based on promotional activities and the ability to meet managed care needs. Novartis reigns for 11th straight quarter.
More Prescriptions Through Learning: The Doctor's Choice
New report finds that neither sales reps nor patient requests are the deciding factor when it comes to physician prescribing habits, information is-the more the better.
DTC Report Finds Consumer Ads Lacking
New study finds that risks and side effects don't get their fair share of time in television advertising. The authors cry out for more educational information in DTC ads--but is it necessary if the ads aren't breaking the law?
